AAM
TXG icon

Advisors Asset Management’s 10x Genomics TXG Stock Holding History

Advisors Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$801K Buy
+20,882
New +$547K 0.01% 864
2025
Q4 		– Sell
-11,368
Closed -$133K – 1506
2025
Q3 		$133K Sell
11,368
-175
-2% -$2.28K ﹤0.01% 1184
2025
Q2 		$134K Sell
11,543
-13,237
-53% -$121K ﹤0.01% 1165
2025
Q1 		$216K Sell
24,780
-805
-3% -$10.1K ﹤0.01% 1096
2024
Q4 		$367K Sell
25,585
-1,232
-5% -$19.4K 0.01% 995
2024
Q3 		$606K Sell
26,817
-674
-2% -$13.9K 0.01% 871
2024
Q2 		$535K Buy
27,491
+2,263
+9% +$59.3K 0.01% 875
2024
Q1 		$947K Buy
25,228
+5,406
+27% +$238K 0.02% 752
2023
Q4 		$1.11M Buy
19,822
+9,357
+89% +$407K 0.02% 700
2023
Q3 		$432K Buy
10,465
+2,903
+38% +$151K 0.01% 937
2023
Q2 		$422K Buy
7,562
+562
+8% +$30.4K 0.01% 979
2023
Q1 		$391K Sell
7,000
-750
-10% -$35K 0.01% 988
2022
Q4 		$282K Sell
7,750
-11,549
-60% -$378K 0.01% 1074
2022
Q3 		$550K Sell
19,299
-1,143
-6% -$43.5K 0.01% 909
2022
Q2 		$925K Sell
20,442
-573
-3% -$29.7K 0.02% 784
2022
Q1 		$1.6M Sell
21,015
-874
-4% -$76.5K 0.02% 659
2021
Q4 		$3.26M Buy
21,889
+2,435
+13% +$373K 0.05% 447
2021
Q3 		$2.83M Buy
19,454
+3,847
+25% +$660K 0.04% 466
2021
Q2 		$3.06M Buy
15,607
+4,922
+46% +$891K 0.04% 455
2021
Q1 		$1.93M Buy
10,685
+6,134
+135% +$1.06M 0.03% 606
2020
Q4 		$644K Buy
+4,551
New +$660K 0.01% 900

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisors Asset Management's TXG Position: Q2 2026 in Review

Advisors Asset Management opened a new position in 10x Genomics (TXG) in Q2 2026: 20,882 shares worth $801K. The stake represents 0.01% of the portfolio and ranks #864 among its holdings. This is a return to the name: Advisors Asset Management previously reported a position in TXG as recently as Q3 2025.

Advisors Asset Management first reported a position in TXG in Q4 2020 and has held it in 21 quarters since. The position peaked at $3.26M in Q4 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Advisors Asset Management held 20,882 shares of 10x Genomics worth $801K as of Q2 2026.
  • 10x Genomics was a new Advisors Asset Management position in Q2 2026.
  • 10x Genomics made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #864 holding.
  • Advisors Asset Management first reported a position in 10x Genomics in Q4 2020 and has held it in 21 quarters since.
  • Advisors Asset Management's 10x Genomics position peaked at $3.26M in Q4 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.